Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa Study of R-OKY-034F in Refractory or Intolerable Unresectable Pancreatic Cancer
jRCT2051200105Phase 1Recruiting
- Sponsor
- J-Pharma
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of R-OKY-034F in pancreatic cancer (PC) (5 arms), sponsored by J-Pharma. Primary endpoint: Adverse events and side effects. Started Sep 2019; status: recruiting.
02
Drugs
R-OKY-034F
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2051200105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200105.